Compositions of GLIPR Fusion Proteins and Methods for the Treatment of Prostate Cancer
AssigneeGlipper Oncology Research, Inc.
InventorsLouis Eugene Burton, Amita Saxena Goel, Divya Goel
Life of this patent
Estimating the term…
Abstract
This invention is directed to fusion proteins comprised of one or more protein sequences of the glioma pathogenesis-related (GLIPR) family of proteins coupled to non-GLIPR protein sequences, to nucleic acid constructs and vectors comprising encoding fusion proteins and peptides, and to methods related to fusion proteins and peptides in the treatment of diseases. In particular, the invention is directed to GLIPR sequences coupled to sequences of antibodies and/or other immune system proteins and peptides, and methods related to fusion proteins in the treatment of prostate cancer.
Claims31
A recombinant peptide comprising a first amino acid sequence of a GLIPR protein coupled to a second amino acid sequence that is not obtained or derived from the GLIPR protein.
A peptide comprising a first amino acid sequence of a GLIPR core protein coupled to a second amino acid sequence comprising a Fc portion of an antibody.
A method of expressing a peptide comprising:
- providing a recombinant vector;
- and
- incubating the recombinant vector in a protein expression system, and
- expression the peptide, wherein the peptide contains a first amino acid sequence of a GLIPR protein coupled to a second amino acid sequence that is not obtained or derived from the GLIPR protein with DAAP coupled to the N-terminus.
Dependencies are inferred from the claim text.